Guttmacher 46d ago

The US Supreme Court has ruled in Louisiana v. FDA to continue allowing telehealth, mailing and pharmacy provision of mifepristone—the first drug in the most common medication abortion regimen in the United States. Kelly Baden, Guttmacher vice president for public policy, explains that while this decision is a relief, we are not celebrating. The case will continue in lower courts where the anti-abortion movement will push their relentless campaign against medication abortion. The science has not changed: mifepristone is safe and effective. #MedicationAbortion #ReproductiveHealth